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Central to the humoral theory of transplantation is production of antibodies by the recipient against mismatched HLA antigens
in the donor organ. Not all mismatches result in antibody production, however, and not all antibodies are pathogenic. Serologic
HLA matching has been the standard for solid organ allocation algorithms in current use. Antibodies do not recognize whole
HLA molecules but rather polymorphic residues on the surface, called epitopes, which may be shared by multiple serologic HLA
antigens. Data are accumulating that epitope analysis may be a better way to determine organ compatibility as well as the potential
immunogenicity of given HLA mismatches. Determination of the pathogenicity of alloantibodies is evolving. Potential features
include antibody strength (as assessed by antibody titer or, more commonly and inappropriately, mean fluorescence intensity) and
ability to fix complement (in vitro by C1q or C3d assay or by IgG subclass analysis). Technical issues with the use of solid phase
assays are also of prime importance, such as denaturation of HLA antigens andmanufacturing and laboratory variability. Questions
and controversies remain, and here we review new relevant data.
1. Introduction
Central to the humoral theory of transplantation so closely
identified with the pioneering work of Terasaki [1, 2] is the
ability of the recipient’s immune system to produce antibodies
against donor mismatched HLA antigens, as well as other
polymorphic systems. HLAmatching determines that a given
transplant can proceed without fear of hyperacute rejection
initially, while at the same time minimizing the chances
of acute and/or chronic alloimmune mediated rejections in
the longer term. In addition, a prominent concern is that
sensitization induced by HLA mismatches may impair the
ability to receive future transplants should the initial one fail.
However, not all mismatches (MMs) result in sensitization,
and not all antibodies preclude transplantation. Furthermore,
not all antibodies detectable after transplantation injure a
graft, whether persisting from pretransplantation or develop-
ing de novo [3]. In this review, we address recent data relative
to 2 important issues regarding antibodies in solid organ
transplantation: the role of epitope analysis in optimizing
HLA matching and the assessment of the pathogenicity of
HLA antibodies.
2. Epitopes in HLA Matching
The determination of the three-dimensional structure of an
HLA molecule by Cn3D modelling together with amino
acid (AA) sequencing led to the definition of polymorphic
AA residues on the surface of the molecule accessible to
antibody binding. An antibody does not recognize an entire
HLA molecule but rather a 15 to 25 AA segment termed an
epitope [4]. Epitopes have an area of 700–900A2 within a
radius of about 15 A˚ that represents the structural epitope.
The corresponding antibody binding surface (paratope) con-
tains 6 complementarity determining regions (CDR), 3 in
the hypervariable region of the light chains and 3 in the
hypervariable region of the heavy chains.
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At the center of an epitope is a polymorphic region of
1 to several AAs within a 3 A˚ radius, termed an eplet or
alternatively the functional epitope. These eplets need not
be continuous AAs, but they must lie upon protein folding
within the 3 A˚ radius. The third and most variable CDR
of the heavy chain lies in the center of the paratope and
recognizes the foreign nature of the mismatched eplet that
defines the functional epitope. The other 5 CDRs allow for
stabilization of the synapse. Eplets are named by their amino
acid sequence number followed by one or more AAs. Many
epitopes are defined simply by the functional epitope (eplet)
alone, whereas others require pairing of that eplet with one or
more additional residues within the structural epitope.These
secondary configurationsmay be superficial on the surface of
the molecule, where they interact with another CDR. Other
times they are hidden, often in the peptide grove, but in this
case they have their effect by altering the configuration of the
functional eplet.
Duquesnoy developed the HLAMatchmaker program
(http://www.HLAMatchmaker.net/) that predicts epitopes
based on surface expression of polymorphic amino acid(s)
located within a 3 A˚ radius. This program has the ability to
determine epitope specificities of highly sensitized individ-
uals and, by intra- and interlocus subtraction, to compare
epletmismatches between 2 individuals (donor and recipient)
[5]. While initially aimed at identifying polymorphisms in
three consecutive amino acids (triplets) of class I alleles,
newer versions consider 1 to several polymorphic amino
acids within a 3 A˚ radius, including both continuous and
discontinuous residues. Class II epitopes have been described
as well [6].
The ability of an epitope to be antigenic has been verified
by monoclonal antibody binding to single antigen beads by
Professor Terasaki’s group. Mouse monoclonal antibodies or
human alloantibodies absorbed and then eluted from single
antigen cell lines, or other sources of single antigens, were
tested with single antigen beads (SAB). AAs common to all
reactive beads were determined by comparing AA sequences
as listed in the Anthony Nolan website. From 1 to 4 AAs
common to all reactive alleles that were exposed on the
surface and within area of 750A2 were used to define an
epitope [7]. By thismethod, 110 class I, 83 class II, 7MHCclass
I chain related geneA (MICA), and 96 cross-reacting epitopes
(found in nontransfused healthy males or cord blood) have
been defined [8] and named TerEps in Professor Terasaki’s
honor.
Duquesnoy and Marrari correlated HLA class I TerEps
with HLAMatchmaker defined epitopes and found 90%
concordance, although about 10% could not be reconciled [9].
Similarly for class II, 49 of 53 HLA-DR TerEps corresponded
to HLAMatchmaker eplets, as did 17 of 18 DQ TerEps [10].
Many more eplets are predicted by HLAMatchmaker that
have not yet been verified by antibody binding. The interna-
tional Registry of AntibodyDefinedHLAEpitopes developed
a website (http://www.epregistry.com.br) to record all possi-
ble HLA epitopes, denoting those that have been antibody
verified [11, 12].This registry contains 5 databases, HLA-ABC,
HLA-DRB, HLA-DQ, HLA-DP, and MICA. As of July, 2016,
289 HLA-ABC epitopes are listed on the website, with 81
noted to be antibody verified. One hundred forty-three HLA-
DRB epitopes have been identified, of which 25 are antibody
verified.
In the case of HLA-DQ, the 𝛼 and 𝛽 chains are considered
separately in the registry with 60 𝛽-chain epitopes (16 anti-
body verified) and 25 𝛼-chain epitopes (3 antibody verified)
listed. The registry does not consider epitopes defined by
specific 𝛼/𝛽 parings but determines epitope specificity solely
by the 𝛽-chain [12]. However, Tambur et al. provide evidence
that specific 𝛼/𝛽-chain parings can determine a DQ epitope,
not either chain in isolation. For example, using Cn3D
software and HLAMatchmaker analysis, 39 of 40 recipients
with failed allografts had de novo DQ antibodies whose
paratope covered both 𝛼 and 𝛽 chains [13].
A given alloantibody may be specific for a particular
eplet, such that every allele carrying that eplet will react with
that antibody. Another alloantibody may also react with that
same eplet, but only if paired with one or more particular
additional residue(s). Alleles containing the eplet without the
additional residue(s) will not react. These additional eplets
are often identical with those of the recipient. This has led
to the “non-self-self” theory of epitope recognition, but these
additional eplets can also be nonself, or even locus specific
monomorphic residues [9]. The additional epitope is usually
on the surface, but it can also be hidden with an effect via
conformational alteration of the functional eplet [9]. The
annotation of such multiply defined epitopes utilizes a “+”
sign between the required eplets.
Over half of defined HLA class I epitopes are restricted
to a single antigen (private epitopes), whereas the others
are shared by 2 or more antigens (public epitopes) [14].
Such public epitopes result in both intra- and interlocus
cross-reactions, often referred to as cross-reactive groups
(CREGs) [13]. This explains the development of apparent
nondonor specific HLA sensitization following solid organ
transplantation, although the epitopes are indeed donor
specific (discussed below). Also, individual alleles usually
contain multiple epitopes. For example, El-Awar et al. found
between 6 and 19 epitopes for eachHLA-A,HLA-B, andHLA-
C antigen [8]. Similarly, HLA-DR antigens had between 8 and
21 epitopes per antigen and DQB chains between 4 and 8.
To better predict and understand the immunogenicity
of HLA molecules, the group from Cambridge assessed the
physiochemical properties of polymorphic AAs that define
eplets, including hydrophobicity and electrostatic charge
disparity [15–18]. The binding of antibody to antigen is
initially determined by electrostatic interactions [19] and
is stabilized by hydrogen bonding, salt bridges, and van
der Waals forces [15, 20, 21]. Kosmoliaptsis et al. assessed
immunogenicity by determining the AA sequences of HLA
molecules (http://www.ebi.ac.uk./imgt/hla/) and then the
number of AA mismatches (AAMs) after interlocus subtrac-
tion between 32 highly sensitized patients and alleles of a
panel of class I SABs exposed to their sera [15]. Both the
presence and magnitude of positive responses were highly
correlated with the number of AAMs, confirming their
prime importance. Independently, however, hydrophobicity
mismatch scores (HMS) and electrostatic mismatch scores
(EMS, determined as the sum of the difference in isoelectric
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points of each mismatched AA) also correlated with reaction
frequency. The immunogenicity of class II antigens was also
shown to be related to the number of AAMs, although it was
not independently related to HMS or EMS by multivariable
analysis [22].
Kosmoliaptsis et al. generated atomic resolution 3D struc-
tural models of HLA class I molecules and calculated the
surface electrostatic potential [17]. Using the public Bw4
and Bw6 epitopes as examples, a remarkable consistency
of the surface electrostatic potential was shown among all
alleles expressing either epitope that reacted with a given
alloantibody. AA substitutions that did not affect surface
potential did not affect binding, whereas those that did affect
surface potential abrogated binding [17, 23].
Finally, immunogenicity of class I HLA mismatched
epitopes may depend on the DR phenotype of the recipient.
The ability of recipient CD4 T-cells to respond indirectly
to donor HLA class I epitopes depends on the ability of
such epitope to be presented in the groove of the recipients
HLA class II DR molecules on antigen presenting B-cells.
Certain anchor amino acids in the peptide are preferred,
and this can be predicted [24]. These epitopes have been
designated “predicted indirectly recognizable HLA epitopes,
HLA class II presented” (PIRCHE-II) [25]. Hence, not all
mismatched eplets can be presented to CD4 cells which
would inhibit appropriate class switching (IgM to IgG) of B-
cells potentially reactive to those eplets. Otten et al. found
49 HLA class I mismatches containing HLAMatchmaker
predicted immunogenic eplets among 21 recipients following
allograft nephrectomy [25]. DSAwere detected for 38 of these
mismatches, and these immunogenic epitopes contained a
larger number of PIRCHE-II compared to nonimmunogenic
ones. Interestingly, 68% of PIRCHE-II epitopes were not part
of HLAMatchmaker designated eplets.
3. HLA Matching and Epitope Analysis
Current solid organ allocation in the US and elsewhere relies
on low resolution serologic HLA matching to determine
calculated PRA values. A major question is whether it is
worth the time and expense to incorporate epitope analysis
in order to better define the immunogenicity of an HLA
mismatch, whether by simply determining theAAM load, the
EMS, documented antibody binding (TerEps), PRICHE-II
epitopes, or the number of epitope mismatches (MMs) using
HLAMatchmaker. Data are accumulating in support of these
methods as a means of predicting subsequent sensitization,
as well as transplant outcomes.
Using the original HLAMatchmaker algorithm that con-
sidered defined epitopes based on polymorphic amino acid
triplets [26], studies on the utility of epitopematching of class
I antigens (HLA-A and HLA-B) in predicting graft survival
compared to standard HLA matching have given conflicting
results. Some studies show a benefit on graft survival [27, 28],
whereas one large study did not [29]. In an earlier study,
Laux et al. compared epitope mismatches (EpMMs) at the
DPB1 locus (defined as amino acid differences in 4 of the 6
hypervariable regions) with conventional allelic matching in
1,478 kidney retransplant patients [30]. Patients with 2 allelic
mismatches but with only 0–2 EpMMs had better 2-year graft
survival than those with 1 allelic mismatch but more than 3
EpMMs.
More recently, Wiebe et al. evaluated the development
of de novo class II (DR and DQ) donor specific antibodies
(DSA) in 286 recipients using the current HLAMatchmaker
program integrated with antibody verification (TerEps) [31].
Locus specific EpMMs were significantly more frequent in
those who developed de novo DSA (dnDSA), whereas high
resolution typing alone was not helpful. The optimal thresh-
olds belowwhere dnDSAwere highly unlikelywere 10 epitope
mismatches for HLA-DR and 17 for HLA-DQ. Overall, 6
epitopes (3 DFR and 3 DQ) were immunodominant, 5 of
which correlated with TerEps. Epitope mismatches at the DP
locus were not associated with development of anti-DP DSA.
In a follow-up study of 195 recipients with prospective
evaluation of medication adherence, Wiebe et al. evaluated
the interaction of noncompliance with these thresholds in
predicting late acute rejections and graft loss [32]. The com-
bination of ≥17 DQ EpMMs and medication noncompliance
was associated with 3 times the rate of rejection and graft
loss as compared to all other groups and ≥10 DR EpMMs
plus noncompliance nearly double so. This study suggests
that patients under consideration for immunosuppression
minimization/withdrawal should have epitope analysis per-
formed.
The Clinical Trials in Transplantation-09 was a multicen-
ter trial aimed at determining if tacrolimus could be safely
withdrawn at 6 months from immunologically quiescent
patients [33]. It was terminated very early after only 21
patients were enrolled (14 in tacrolimus withdrawal arm)
due to safety concerns, as 8 of the 14 withdrawal patients
developed acute rejection and/or dnDSA. Using the DQ
EpMM cut-off of 17 noted above, 7 of 13 patients with ≥17 DQ
EpMMs as defined byHLAMatchmaker developed dnDSA as
compared to 0 of 8 with <17 EpMMs (𝑝 = 0.028). Obviously,
these numbers are too small to draw any firm conclusions,
but together with the data of Wiebe et al. cited above they do
indicate further research is warranted.
Sapir-Pichhadze et al. compared HLA-DRB1/3/4/5,
DQA1, and DQB1 EpMM loads using HLAMatchmaker
in 52 patients with transplant glomerulopathy (TG) and
104 case-controls [34]. A significantly increased odds ratio
(OR) for having TG was found for the highest and middle
tertiles of HLA-DR + DQ MMs as compared to the lowest
tertile. This held whether modelled as a binary variable or
a continuous variable. Surprisingly, DR eplet load appeared
to confer a greater risk than DQ eplet load, similar to the
findings of Kosmoliaptsis et al. for the immunogenicity of
class II HLA [16].
The significance of epitope matching on sensitization
following allograft failure has been studied. Singh et al. from
our institution studied 66 previously nonsensitized patients
that received a kidney transplant that subsequently failed and
found that 34 became highly sensitized (cPRA ≥ 80%) [35].
Epitopes were assessed by HLAMatchmaker. Multivariable
analysis revealed that DQB1 EpMMs, immunosuppression
withdrawal, and the graft intolerance syndrome were signif-
icantly associated with high sensitization, whereas HLA-A,
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HLA-B, DRB1/3/4/5, andDQA1 EpMMswere not.These data
highlight the potential importance of epitope matching in
those who may require retransplantation, such as pediatric
or young adult cases.
Lachmann et al. studied 54 patients with failed kidney
allografts: 28 with concurrent nephrectomy/immunosup-
pression withdrawal (IWD), 14 with just nephrectomy (prior
IWD), and 12 with just IWD [36]. HLA antibodies were
detectable in 100%, 100%, and 92%, respectively. An increase
in breath and intensity of antibodies against class I antigens
followed nephrectomy, whereas an increase in class II fol-
lowed IWD. In a subgroup of 9 patients with concurrent
nephrectomy/IWD, epitope specificities were determined
by monoclonal antibody binding (TerEps). Overall, they
identified 26 mismatched donor epitopes in these 9 patients.
Although only 18 of 243 class I antibodies in these patients’
serum could be called DSA by traditional matching, 145
of the remaining 225 non-DSA HLA were actually donor
epitope specific antibodies (DESA). These data again suggest
that epitopematchingmay reduce sensitization after allograft
failure, an issue of prime importance for those requiring
retransplantation.
Kosmoliaptsis et al. studied 131 patients with a failed first
kidney transplant. Initially, they determined that standard
matching (0, 1, or 2 MMs) at HLA-A, HLA-B, HLA-C, DRB1,
3, 4, 5, and DQB1 loci contributed independently to HLA
sensitization with an incremental effect [37]. Subsequent-
ly, they determined in this same cohort that the AAM
score (AMMS), the epitope mismatch score (EpMMS),
and the electrostatic mismatch score (EMS) contribut-
ed independently to sensitization [18]. All 3 scores independ-
ently correlated to HLA-DRB1/3/4/5 and DQ DSA, but only
EMS did so with HLA-A and HLA-B DSA. For these analyses
they used the algorithms freely available online (http://www
.hlaimmunogenicity.org/download/Cambridge HLA Class
I Immunogenicity Algorithm.xls for class I and http://www
.hlaimmunogenicity.org/download/Cambridge HLA Class
II Immunogenicity Algorithm.xls for class II).
In summary, it is still unclear whether epitope matching
should be incorporated into the HLA matching algorithm of
all potential kidney transplants. Optimally, it requires high
resolution (4 digit) typing, as compared to the low resolution
(2 digit) typing currently required by UNOS, which may add
significantly to cost and labor [38]. Technology is improving,
however, with turnaround time down to several hours.
Furthermore, the most likely 4-digit allele can be statistically
predicted from serologic typing based on demographic fea-
tures and haplotype frequencies [39], as is used by the Be
The Match Registry of the National Marrow Donor Program
(https://bioinformatics.bethematchclinical.org/). Some feel
this approach is warranted [38], whereas others feel sufficient
information can be obtained from serologic matching with
consideration of known CREGs in place of epitopes [40].
Directionality was noted in the protective effect of CREG
matching, a finding suggesting that more than just AMMs
are involved [40]. The optimal method of epitope analysis
is also unclear, be it a simple AMMS, an HLAMatchmaker
defined EpMMS, an antibody defined EpMMS, PIRCHE-II,
or an EMS.
In our opinion, all highly sensitized patients on the
waiting list should have epitope analysis by some method to
better define acceptable and unacceptable mismatches. The
Eurotransplant Acceptable Mismatch program now incorpo-
rates the HLAMatchmaker program for such analysis [41]. In
patients likely to need another transplant, epitope analysis for
optimal matching of the first transplant is also warranted. At
least one pediatric transplant center now incorporates class II
epitope matching using HLAMatchmaker when confronted
with 2 potential donors (e.g., parents) [42], and we feel
this should be the norm. Finally, the degree of EpMM
should potentially be assessed in any patient considered for
immunosuppression minimization or withdrawal, although
more data are clearly required.
4. Pathogenicity of HLA Antibodies
Not all antibodies capable of reacting with a kidney allograft
are necessarily pathogenic, and significant variability exists
in those that are. Initially, the detection of HLA antibod-
ies was dependent on their ability to lyse lymphocytes in
the presence of complement, the complement dependent
cytotoxicity crossmatch (CDCXM) assay, which is still in
use as the final determinant of the safety of a particular
transplant [43]. Subsequently, flow cytometry crossmatch
(FCXM) technology was developed with higher sensitivity,
and it remains in use for the majority of current kidney
transplants. In general, outside of desensitization protocols,
the presence of DSA detected by either type of crossmatch
would abrogate the transplantation, but various exceptions
exist [44].
The current standard, however, for evaluating HLA anti-
bodies inmost laboratories involves HLAmolecules attached
to a solid phase matrix, typically a bead, which may contain
multiple HLA antigens from multiple cell lines per bead
(mixed antigen beads), multiple HLA antigens from a single
cell line per bead (phenotypic beads), or a singleHLA antigen
(single antigen beads or SAB) [45].The breath of sensitization
(“panel reactive antibody” or PRA) is determined along
with donor specificity (DSA). These bead-based assays are
typically used in conjunction with the cell-based assays
(CDCXM, FCXM) to determine if a given transplant should
proceed, a decision that also depends on the immunologic
risk of a recipient as determined by sensitizing events (prior
transplantation, pregnancy, and transfusions), PRA, quality
of life on dialysis, life expectancy, and so forth. Various
algorithms have been in use [46]. In our laboratory atThomas
Jefferson University Hospital, SABs are used for screening,
whereas other centers prefer a screening assay with beads
derived from cell lines [47]. In our laboratory all patients
undergo autocrossmatch, T and B-cell CDCXM, and FCXM
in all live donors and any deceased donor when recipient has
any past or current sensitization. If SABs used for screening
are completely negative in a patientwith no sensitizing events,
crossmatching may be superfluous [44, 48].
Features that are possibly significant in determining the
pathogenicity of any given DSA include antibody isotype
(IgMversus IgG), class specificity (HLAclass I versus class II),
mean fluorescence intensity (MFI), antigenic specificity (i.e.,
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native HLA class I molecules (nHLA) complexed with 𝛽2-
microglobulin and peptide versus denatured HLA (dHLA)
containing 𝛼-chain only), titer, and ability to fix complement.
The latter may be demonstrable by detection of C4d in
allograft tissue histologically, or by in vitro detection of C1q,
C3d, or C4d on synthetic surfaces containing alloantigen epi-
topes after exposure to patient serum. Also, immunoglobulin
subclass determination may be relevant given the differential
ability of IgG subclasses to fix complement and recruit
inflammatory cells.
Before transplantation, the first order is to predict which
DSA will result in a positive crossmatch to obviate unneces-
sary incompatible offers, as well as to enhance the chances
of highly sensitized patients receiving a kidney. In addition,
the ability to predict which pretransplant DSA will result
in acute antibody-mediated rejection (AAMR) and/or affect
long term graft survival (GS) is critical to guide post-
transplantation surveillance and immunosuppression. Any
DSA detected after transplantation, whether persisting from
pretransplantation or developing de novo, requires the same
scrutiny owing to their documented association with both
acute and chronic AMR, as well as graft and patient survival.
5. Antibody Isotype
IgM autoantibodies are not pathogenic, although they may
result in a positive CDCXM that would be determined by a
concurrent positive auto-CDCXM. IgM alloantibodies have
been considered to be of low or no potential pathogenicity
[49–51], and their presence has even been linked to a
more favorable outcome [52]. By contrast, reduced allograft
survival has been reported [53]. More recently, a potentially
pathogenic role for IgM alloantibodies was detected in
eculizumab-treated patients receiving a positive crossmatch
kidney transplant, as posttransplantation IgM DSA were
found in 3 of 3 such patients with early AAMR, as compared
to 1 of 23 without rejection (𝑝 = 0.006) [54, 55]. In a study of
179 nonsensitized kidney transplant patients, 100 developed
DSA, including 53 with IgM alone and 42 with concurrent
IgG DSA [56]. A complete IgG subclass profile was not
performed, although IgG3 specifically was determined. Only,
5 had IgG DSA without any detectable IgM. IgM alone was
not associated with reduced allograft survival, but the 19 IgG3
positive patients with persisting IgM DSA did have reduced
allograft survival (𝑝 = 0.02). IgM alloantibodies may be
pathogenic, but more research is obviously needed to clarify
this issue. In any case of AAMR not explainable by IgG
alloantibodies, we would search for IgM antibodies.
6. Class Specificity
Preformed class I antibodies are the major mediators of
hyperacute rejection as well as early AAMR. Class II anti-
bodies can also be involved, alone or in combination with
class I antibodies [57, 58]. Class specificity of pretransplant
DSA does not seem to be an independent variable for
determining adverse outcomes bymultivariable analysis [59–
61]. Class II DSA after transplantation, however, are more
deleterious than those against class I for predicting risk of TG
and GS [62–64]. This is especially true for DQ antibodies,
which are also the most common to develop de novo after
transplantation [62, 64, 65]. Several factors may explain the
prominence ofDQantibodies after transplantation, including
linkage disequilibrium with DR [66], cis/trans combinations,
greater potential peptide variability, and a high degree of self-
chain paired with nonself epitope [67]. Further support of
the importance of class II loci, especially DQ, comes from a
recent registry study fromAustralia and New Zealand, where
mismatches at the DQ locus were significantly associated by
multivariable analysis with any rejection or specifically late
rejections. In those with 1 or 2 mismatches at the DR locus,
any mismatch at the DQ locus was significantly associated
with AMR as well [68].
7. Mean Florescence Intensity
The single antigen bead assays currently in use are approved
as semiquantitative analyses only. The way to assess the
potential concentration of antibodies is usually by mean
fluorescence intensity (MFI). Only an imperfect correlation
exists, however, between MFI and true antibody concentra-
tion. Variability in MFI may arise frommanufacturing issues
regarding density and quality of HLA antigens attached to
SAB [69], as well as operator implementation of protocols
[45]. Even under conditions of optimal standardization and
normalization, the coefficient of variation (CV) between
laboratories is 20% to 25% at best [45]. This is above the
standard FDA requirement of 15–20% maximal CV to be
considered a quantitative test. Numerous factors addition-
ally may alter the relationship between observed MFI and
actual antibody concentration and pathogenicity. In states
of marked antibody excess where beads are completely
saturated,MFI would underestimate antibody concentration.
This can be shown by simple dilution, which would not result
in a corresponding reduction of MFI. A given antigen may
have multiple alleles, each represented on individual beads,
and this would tend to lower the MFI relative to an antigen
with fewer alleles represented [70]. An antibody directed
against a public epitope (e.g., Bw4) would be spread out
over multiple beads, resulting in a falsely low MFI, as would
relatively low antigen expression with use of phenotype or
mixed antigen screening beads [71].
A well-known phenomenon resulting in amarked under-
estimation of true antibody concentration is often termed the
“prozone effect.” Initially, this was ascribed to the inability
of the detection antibody to bind the HLA antibody on the
bead as a result of interference from bound C1.More recently,
the downstream complement activation products C4d and
especially C3d have been shown to be responsible [72]. Again,
a prozone effect can be uncovered by simple dilution, where
theMFIwould in this case increase. Also, it can be reversed by
disruption of the C1 component of complement by ethylene-
diaminetetraacetic acid (EDTA), dithiothreitol (DTT), or
heating [73]. Heat andDTTdenature C1q, and EDTA chelates
calcium to inactivate C1q binding [74]. Interference from
IgM antibodies has also been reported, [75] as well as from
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undefined serum factors, and these effects can be mitigated
by hypotonic dialysis or DTT [76]. At a minimum, we feel
that some methods, such as EDTA or a simple one-time
dilution, should be routinely used to eliminate concerns over
the prozone effect.
Alloantibodies reacting only with denatured class I
antigens would inappropriately inflate the MFI relative to
pathogenicity and are discussed below. Also, alloantibod-
ies that do not activate complement in vitro may be less
pathogenic. This too is discussed below.
Evolution of MFI over time may be more meaningful
than an isolated reading. Burns et al. studied the early
posttransplant course of 41 crossmatch-positive patients
using B-cell flow crossmatch intensity and its correlate, total
DSA MFI [58]. All patients had a decrease in intensity by
day 4, presumably by adsorption to the graft. These levels
remained low in those who did not develop an AAMR but
increased significantly in those who did, a result suggesting
that serial MFI monitoring may better identify the poten-
tial pathogenicity of preformed DSA. In studying patients
receiving a FCXM-positive kidney transplant, Kimball et
al. showed by SAB analysis that persistence of preformed
DSA as compared to their elimination during the course of
the first posttransplantation year was significantly associated
with AAMR (43% versus 3%), chronic rejection (43% versus
0%), and graft loss (33% versus 5%) [77]. Dieplinger et al.
studied 24 patients with dnDSA in the first 2 years after
transplantation and found that, over an additional 24months,
16 lost significant estimatedGFR (>25%) [78]. InitialMFIwas
not different as compared to the 8 with preserved GFR, but
the subsequent peak MFI and delta MFI (>20% or >50%)
were significantly higher. Altogether, these 3 studies suggest
that MFI evolution over time is much more meaningful
than any single isolated reading. Nevertheless, more data are
clearly needed before immunosuppression can be routinely
altered by such information.
Most patients with DSA have antibodies reacting with
more than one antigen. In those with multiple DSA, the
best way to determine the actual risk for a particular patient
remains uncertain. For example, risk may be determined by
the single highest MFI. By contrast, the algebraic sum of
the MFIs of all DSA may be more relevant. When multiple
DSA are present, it would seem reasonable to consider the
sum of their MFIs when they share an epitope or epitopes,
as opposed to the single immunodominant MFI [47]. Some
studies suggest that summing DSA is superior to using the
immunodominant MFI when multiple DSA exist [69, 79].
Most recently, Visentin et al. found a greater predictability of
positive crossmatches using immunodominant MFI of class
I DSA as compared to the sum of class I DSA MFI [80]. The
specific use of epitope analysis to answer this question has not
been addressed.
8. In Vitro Complement Activation Assays
The C1q in vitro assay detects C1q on SAB after adding
human C1q, and many studies have evaluated its role in
predicting outcomes. This assay would appear to be an
excellent way to assess antibody pathogenicity given the
known role of complement in mediating antibody injury
[81]. Antibodies may induce injury by mechanisms other
than activating complement, however, including antibody-
dependent cellular cytotoxicity [82] and direct antibody acti-
vation of endothelial cells [83]. Furthermore, C1q-positivity
may merely be a surrogate for antibody titer [84, 85]. In
order to activate C1q, IgG molecules must be in close
proximity to typically form a hexamer [86], which requires
a high concentration of antibody. Yell et al. demonstrated
that concentration of relatively lower MFI C1q-negative DSA
to higher concentration uniformly converted them to C1q-
positive, and dilution of C1q-positive DSA converted them to
C1q-negative [87]. Low MFI sera may contain C1q-positive
DSA, and this is explainable by the prozone effect, at least in
some instances [88]. Likewise, high MFI DSA may be C1q-
negative [89], possibly if restricted to noncomplement fixing
IgG2/IgG4 subclasses (rare), IgMantibodies, abnormalities of
IgG Fc glycosylation [90], or due to variable percentages of
denatured HLA molecules on individual SAB [91].
In an elegant technical study, Taylor et al. studied 25
highly sensitized, wait-listed patients and looked at the
relationship between pan-IgG SAB MFI and C1q-positive
MFI in order to assess factors affecting this relationship [91].
Sera were compared neat and following EDTA to abrogate
complement interference and simple 1 : 20 dilution to detect
very high titers. Also, the percent of denatured HLA class
I chains (without 𝛽-2 microglobulin) was assessed as a
contributing factor. There was a poor correlation between
neat pan-IgG MFI and C1q-positive MFI (𝑟2 = 0.42). The
correlation increased following EDTA (𝑟2 = 0.57) and
dilution (𝑟2 = 0.77). A consistent expression of intact HLA
(with 𝛽-2 microglobulin) molecules per SAB was found for
allHLA-A andB specificities andmostC specificities.Marked
variability, however, existed in the amount of denatured HLA
molecules between bead populations, ranging from 19% to
91% (mean 69%). The greater the percentage of denatured
HLA the lesser the correlation between pan-IgG MFI and
C1q-positive MFI, irrespective of which assay was used.
Restricting diluted serum to bead populations with ≤30%
denatured HLA increased the 𝑟2 to 0.86. These data sug-
gest that C1q positivity merely reflects MFI if appropriately
assessed and does not add significant additional information
to justify the excess cost.
Nevertheless, many studies have assessed the ability of
C1q-positive DSA to predict adverse outcomes. As we [92]
and others [93] have reviewed, at best only conflicting
evidence exists to support the pretransplantation use of this
assay for such prediction. After transplantation, however,
there appears to be a significant relationship [94], and new
studies have appeared in the past 2 years to further this
notion.
Calp-Inal et al. studied 284 patients with no pretrans-
plant DSA (group 1) and compared them to 405 patients
from an earlier era (group 2) with unknown pretransplant
status [95]. Over 2.5 years of prospective follow-up, 11%
of group 1 patients developed de novo DSA, of which 4%
were C1q-positive and 7% C1q-negative. AAMR was signif-
icantly higher (45%) with C1q-positive DSA as compared to
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C1q-negative DSA (5%) and no DSA (1%) with 𝑝 < 0.001.
The incidence of chronic AMR/TG was significantly higher
as well (36% versus 5% versus 2%, respectively, 𝑝 < 0.001).
Overall, GS was nonsignificantly reduced with C1q-positive
DSA. Similar results were obtained with group 2 patients,
with 19% having detectable DSA after transplantation (8%
C1q-positive and 11% C1q-negative).
Guidicelli et al. studied 346 nonsensitized patients with
DSA evaluation at 2 and 5 years with 10-year follow-up [88].
At 2 years, 25 had de novo DSA, 12 C1q-positive and 13 C1q-
negative. At 5 years, 30 were de novo DSA positive, 8 C1q-
positive and 22C1q-negative. Patients withC1q-negativeDSA
at 2 years had the same death censored GS (DCGS) at 5
years as DSA-negative patients, but C1q-positive patients had
significantly worse DCGS, a result indicating a rather rapid
effect on GS if C1q-positive. Those with C1q-positive results
at either 2 or 5 years had worse DCGS at 10 years than those
without DSA. Interestingly, those with C1q-negative DSA at
both 2 and 5 years also had worse DCGS than those without
DSA, a result suggesting a slower but still pathogenic effect of
these C1q-negative DSA.
Lefaucheur et al. studied 125 patients (of 635 consecutive
kidney transplants) with DSA detected in the first posttrans-
plant year, with 42% of immunodominant DSA being C1q-
positive [96]. By multivariable analysis (MVA) C1q-positivity
was independently associated with allograft loss (HR3.6, 𝑝 =
0.03). In a larger follow-up study of 851 consecutive kidney
transplants that included the same patients, Viglietti et al.
found that 13% were DSA positive at transplantation and
23%were positive after transplantation [97]. C1q-positivity at
either time improved significantly the 𝑐 statistic for allograft
loss independent of MFI and significantly improved the net
reclassification index (NRI) at both time points as well.
In 69 patients with AAMR, Sicard et al. compared the
ability of theDSA to activate complement in vitro by detecting
C1q or C3d with flow bead assays [98]. By MVA, C3d-
positivity was significantly associated with graft loss, whereas
C1q-positivity was not. This result was validated in an
independent cohort. Even C3d+ patients with a lowMFI had
reducedGS. Similarly, Comoli et al. studied 114 nonsensitized,
pediatric, first kidney transplant recipients and found that 39
developed dnDSA at a median of 25 months [99]. Of these,
25 were C1q-positive, and 9 were additionally C3d-positive.
Some that were C1q-negative on initial detection progressed
to C1q-positive over time, and some of these further pro-
gressed to C3d-positive, all with the same antigenic speci-
ficity. Any such progression was associated with significant
increase in MFI. C3d-positivity significantly enhanced the
predictability of dnDSA for 10-year graft survival.
To summarize, while these new data are promising,
they must be validated in other populations and tested
prospectively. It remains unclear whether determination of
in vitro complement activating capability by C1q or C3d
binding on SABs justifies the additional cost for routine
use, although there certainly may be a role in higher risk
candidates. Prospective outcome studies with therapy based
on such testing could determine the optimal approach.
9. IgG Subclass Determination
Given the pathogenic potential of complement activation
by IgG HLA antibodies, interest has arisen regarding IgG
subclass determination as ameans of assessing the pathogenic
potential of DSA. The germline order of IgG subclasses
begins with IgG3 and proceeds through IgG1, IgG2, and IgG4,
sequentially. The strength of complement activation parallels
this order with IgG3 and IgG1 considered strong activators
and IgG2 and IgG4 weak or not at all. The vast majority
of HLA antibodies as detected by SABs are composed of
strong complement activators (IgG1 and/or IgG3) alone or
in combinationwithweak/nonactivators (IgG2 and/or IgG4).
Isolated weak and/or nonactivators in the absence of strong
activators are distinctly unusual, ranging from about 1%
[100, 101] to 5% [102, 103] of SAB reactions. Hence, strong
activators are nearly always detectable, and the absence of
C1q positivity does not rule out their presence [103]. As we
reviewed previously [92], themajority of evidence at that time
did not support routine subclass determination.
The recent study by Lefaucheur et al. (noted above for
C1q) evaluated the characteristics of DSA detected in the first
year after transplantation in 125 patients with biopsy, either
for indication or as a 1-year protocol, and with 5-year follow-
up [96]. These DSA were evaluated for MFI, C1q binding,
and subclass distribution. Altogether, 40% of patients had a
clinical AAMR, 29% had subclinical AAMR, and 30% were
free of AAMR. As in prior studies, IgG1 was most often
found (75%), followed by IgG2 (44%), IgG3 (28%), and IgG4
(26%), and 17% had no subclass detectable with a relatively
low MFI by pan-IgG. Only 4% had just noncomplement
fixing IgG2 and/or IgG4. Overall, 32 of 35 IgG3-positive
patients had clinical AAMR, and IgG3 was the only class
significantly associatedwith shortenedGS including byMVA.
IgG4-positivity was associated with subclinical AAMR and
more chronic lesions on biopsy. Viglietti et al. expanded this
database to 851 patients and found by MVA that detection
of IgG3-positive DSA, either at the time of transplantation
or after transplantation, significantly increased the 𝑐 statistic
for allograft survival at both time points and improved the
NRI as well [97]. While very provocative, these data require
independent validation.
10. Antibody Titration
Antibody strength is a measure of antibody affinity and
avidity and is reflected in the kinetics of antigen-antibody
dissociation [104]. Affinity measures the strength of interac-
tion between an antibody paratope and the corresponding
epitope and denotes the relative amount of antigen-antibody
complex at equilibrium. Avidity is a more global measure of
strength and includes affinity, but also valency and structural
orientation (e.g., antigen bound to a solid phase matrix).
Strength can be determined by serial dilution studies, with
the titer being the dilution at which the test becomes negative.
Relative strengths of different antibodies can then be defined
as the relative MFIs at the highest dilution.
Tambur et al. accumulated over 7000 individual data
points from 27 class I assays and 49 class II assays of 55
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sensitized patients [104]. A prozone effect, defined here as at
least a 100% increase from neat to peak MFI, was detectable
for at least one antibody specificity in 71% of patients and
for at least one specificity in 40% of class I assays and 65%
of class II assays, although overall less than 1% of beads
were affected. The effect was often but not always abrogated
with EDTA treatment. Looking at the correlation with the
ability to fix complement (via the C1q assay), a much higher
correlation coefficient was found for the peak MFI on serial
dilutions as compared to the standard neat MFI. An even
higher correlation was obtained with titers. This study also
showed the relative insensitivity of C1q assay, as titers of 1 : 16
to 1 : 32 represented a threshold for C1q positivity for class I
antibodies and 1 : 32 to 1 : 64 for class II.
In a follow-up study, the neat IgG MFI, C1q-positive
MFI, and antibody titers were compared for their ability to
best monitor the effect of desensitization procedures on 40
patients [105]. Titration studies provided a better estimation
of strength and more uniformly demonstrated reduction
of antibody in response to treatment. Serial titration does
add cost, and it remains to be determined by prospective
studies the actual role in clinical practice. In our opinion, a
one-time dilution may be sufficient to rule out the prozone
phenomenon, but serial dilutions would be in order for
desensitization protocols or to monitor treatment.
11. HLA Antigen Conformation
Class I HLA molecules are present in vivo on the cell
surface of activated lymphocytes both as intact trimolecular
complexes (𝛼-chain, 𝛽2-microglobulin, and peptide) and
open conformers (𝛼-chain only) [106].These isolated (“dena-
tured”) 𝛼-chains (dHLA) may homodimerize and/or bind
to intact class I molecules to enhance antigen presentation
[107]. They can also heterodimerize with other cell surface
receptors, such as the insulin receptor, and alter cell signaling
[107, 108]. Such dHLA exist in varying proportions on SAB as
a result of different manufacturing techniques as compared
to multiantigen screening beads [109], but they may exist
on mixed antigen beads as well [110]. Antibodies specific
for intact HLA class I can be determined by SABs that lack
dHLA, so-called iBeads [111]. Unfortunately, iBeads are no
longer commercially available [80].The relative proportion of
intact HLA molecules and dHLA molecules on SABs can be
assessed by relative binding ofmonoclonal antibodies specific
for intact HLA (W6/32) or dHLA (HC-10) [112].
Alternatively, antibodies against dHLA can be detected by
acid treating regularmixed antigen or SABs, as acid treatment
will denature all HLA antigens on the beads. Such treat-
ment would significantly reduce MFI of antibodies reactive
with epitopes determined by the trimolecular structure of
intact (nondenatured) HLA (nHLA). During the process of
denaturing, hidden epitopes may be exposed that are not
accessible to binding on intact antigens [14]. Hence, the MFI
of a particular serum against a particular bead may markedly
increase after acid exposure, thereby indicating the antibodies
are directed against dHLA [14, 113]. If the MFI markedly
decreases, the antibodies are directed against nHLA. If it stays
roughly the same, they are also against nHLA, but anti-dHLA
may coexist [113]. Interestingly, antibodies against dHLAmay
be found in nontransfused healthy male patients as well as in
cord blood, a finding suggesting they arise by cross-reactivity
with environmental antigens, vaccines, or microorganisms
[14, 114].
Other studies indicate anti-dHLA antibodies do not
shorten GS. In a study of 156 sensitized patients with 241 class
I DSA by regular SAB analysis before transplant, Otten et
al. found that 152 DSA were also positive by iBeads and 28
were found only by dHLA beads [112]. Allograft survival was
significantly reduced in thosewith either regular SABpositiv-
ity or iBead positivity as compared to nonsensitized patients,
whereas in the 20 patients with 28 isolated antibodies to
only dHLA,GSwas not different from controls. Furthermore,
iBead-positive DSA were associated with sensitizing events,
whereas dHLA only DSA were not. Likewise, Cai et al.
found that 379 (38%) of 994 KT recipients had class I HLA
antibodies by mixed antigen bead testing, including 200
with antibodies also reacting with acid-eluted mixed antigen
beads (dHLA) and 179 lacking these antibodies (i.e., only
containing anti-native HLA antibodies) [110]. Overall GS was
equal between sensitized and unsensitized recipients, but it
was significantly lower in the 179 that had only anti-native
HLA and not in those who also had anti-dHLA.
C1q positivity may signify pathogenicity of antibodies
against denatured HLA antigens. Cai et al. studied 975
kidney transplant patients and found that 30%had antibodies
against denatured HLA class I, class II, or MICA, using heat-
treatment of mixed antigen beads as a means of denatura-
tion [115]. Overall, 8.5% were C1q-positive and 21.5% C1q-
negative [115]. Again there was no difference in graft survival
comparing those with to those without these antibodies
against denatured antigens. However, the 8.5% with C1q-
positive dHLA antibodies had lower graft survival compared
to recipients with only C1q-negative anti-dHLA or no such
antibodies. C1q-positivity was significantly associated with
graft failure due to AMR and mixed AMR/CMR.
In summary, MFI on neat serum is clearly an imperfect
measure of antibody concentration, strength, and potential
pathogenicity. At a minimum, treatment with EDTA or a
simple one-time dilution should be routine. Formal titration
is indicated in desensitization procedures and possibly in the
course of treating acuteAMR.The role of in vitro complement
activating capability as a routine or in the management of
the individual patient remains uncertain at this time, as
does IgG subclass determination. Consideration of dHLA
to explain a high MFI would be most applicable in those
without sensitization history. Most importantly, bead-based
data must not be used in isolation, but only in conjunction
with cell-based assays and with appropriate consideration
of sensitization history and other clinical features of any
particular patient.
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